Sumaxin TS

SUMAXIN TS- sulfacetamide sodium and sulfur lotion
Medimetriks Pharmaceuticals, Inc.

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

DESCRIPTION: Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl] acetamide, monosodium salt, monohydrate. The structural formula is:

structure SS
(click image for full-size original)

Each mL of Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash contains 90 mg of sodium sulfacetamide and 40 mg of sulfur in a formulation consisting of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glyceryl stearate/PEG-100 stearate, green tea, magnesium aluminum silicate, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl taurate, sodium thiosulfate, stearyl alcohol, xanthan gum.
Each mL of Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS contains 80 mg of sodium sulfacetamide and 40 mg of sulfur in a formulation consisting of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glyceryl stearate, green tea, magnesium aluminum silicate, methylparaben, PEG-100 stearate, propylparaben, purified water, sodium cocoyl isethionate, sodium methyl cocoyl taurate, sodium thiosulfate, stearyl alcohol, xanthan gum.

CLINICAL PHARMACOLOGY: The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth.
While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS: Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS are indicated for the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS: Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS are contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS are not to be used by patients with kidney disease.

WARNINGS: Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.
FOR EXTERNAL USE ONLY. Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

PRECAUTIONS: General – If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for Patients – Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility – Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCY: Category C – Animal reproduction studies have not been conducted with Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS. It is also not known whether Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS: It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash and Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS are administered to a nursing woman.

PEDIATRIC USE: Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS: Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE AND ADMINISTRATION: Apply Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash or Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS once or twice daily to affected areas, or as directed by your physician. Wet skin and liberally apply to areas to be cleansed. Massage gently into skin for 10-20 seconds, working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing off Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash or Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS sooner or using less often.

HOW SUPPLIED: Sumaxin® (sodium sulfacetamide 9% and sulfur 4%) Wash is available in a 16 fl. oz. (473 mL) bottle, NDC 43538-130-16.
Sumaxin® (sodium sulfacetamide 8% and sulfur 4%) TS is available in a 16 fl. oz. (473 mL) bottle, NDC 43538-160-16.

Store at controlled room temperature 15°-30° C (59°-86° F). Protect from freezing.
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.


MEDIMETRIKS
PHARMACEUTICALS, INC.
363 Route 46 West
Fairfield, NJ 07004-2402 USA
www.medimetriks.com
Manufactured by:
Groupe PARIMA, Inc.
Montreal, QC H4S 1X6 CANADA

label
(click image for full-size original)

carton
(click image for full-size original)
SUMAXIN TS sodium sulfacetamide and sulfur lotion
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:43538-160
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
SULFACETAMIDE SODIUM (SULFACETAMIDE) SULFACETAMIDE SODIUM 80 mg in 1 mL
SULFUR (SULFUR) SULFUR 40 mg in 1 mL
Inactive Ingredients
Ingredient Name Strength
ALOE
BUTYLATED HYDROXYTOLUENE
CETYL ALCOHOL
DISODIUM OLEAMIDO MEA-SULFOSUCCINATE
EDETATE DISODIUM
GLYCERYL MONOSTEARATE
GREEN TEA LEAF
MAGNESIUM ALUMINUM SILICATE
METHYLPARABEN
POLYOXYL 100 STEARATE
PROPYLPARABEN
WATER
SODIUM COCOYL ISETHIONATE
SODIUM THIOSULFATE
STEARYL ALCOHOL
XANTHAN GUM
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:43538-160-16 1 BOTTLE, PUMP (BOTTLE) in 1 CARTON contains a BOTTLE, PUMP
1 473 mL in 1 BOTTLE, PUMP This package is contained within the CARTON (43538-160-16)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 09/02/2010
Labeler — Medimetriks Pharmaceuticals, Inc. (019903816)
Registrant — Groupe PARIMA, Inc. (252437850)
Establishment
Name Address ID/FEI Operations
Groupe PARIMA, Inc. 252437850 manufacture

Revised: 09/2010 Medimetriks Pharmaceuticals, Inc.

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2020. All Rights Reserved.